Barrier Therapeutics is a pharmaceutical company focused on developing and commercializing products in the field of dermatology. We are committed to developing innovative products that address major medical needs in the treatment of dermatological diseases and disorders of
the skin.

We currently market three pharmaceutical products in the United States: Vusion^® (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, Xolegel^® (ketoconazole, USP) Gel, 2%  and Solagé^® (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

In addition to our marketed products, we have other product candidates in various stages of clinical development for the treatment of a range of dermatological conditions, including onychomycosis, psoriasis, acne,  skin allergies and superficial fungal infections.

Our Corporate Headquarters is located in Princeton, New Jersey, and we have a wholly-owned subsidiary in Geel, Belgium.